Cellectis gains first therapeutic licence to Japanese iPS cell technology
This article was originally published in Scrip
The French genome engineering firm Cellectis has signed two non-exclusive agreements that give it access to patents deriving from the research on induced pluripotent stem (iPS) cells being conducted at the University of Kyoto in Japan.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.